Healthcare >> Analyst Interviews >> August 2, 2004
Matthew Kaplan focuses on drug delivery and gene therapy stocks for Punk
Ziegel & Company. He was previously a Biotechnology Analyst at Evolution
Capital and head of the life sciences team at The Carson Group. Prior to
that, he was a Research Associate with the Albert Einstein College of
Medicine/Montefiore Hospital Department of Cardiology, where he co-
authored seven articles on gene regulation in the heart as well as a
book chapter titled 'Direct Cardiac Gene Transfer in vivo,' in Methods
in Molecular Biology. He received a BS in Biology from the University of
Michigan and studied Cellular and Molecular Biology at Columbia
University. Profile
within the overall equity research programs at Punk Ziegel & Company?
Mr. Kaplan: Punk Ziegel is a boutique investment
